These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36142819)

  • 1. Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein.
    Chen YL; Lin JJ; Ma H; Zhong N; Xie XX; Yang Y; Zheng P; Zhang LJ; Jin T; Cao MJ
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography.
    Ubah OC; Lake EW; Gunaratne GS; Gallant JP; Fernie M; Robertson AJ; Marchant JS; Bold TD; Langlois RA; Matchett WE; Thiede JM; Shi K; Yin L; Moeller NH; Banerjee S; Ferguson L; Kovaleva M; Porter AJ; Aihara H; LeBeau AM; Barelle CJ
    Nat Commun; 2021 Dec; 12(1):7325. PubMed ID: 34916516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD.
    Liu X; Wang Y; Sun L; Xiao G; Hou N; Chen J; Wang W; Xu X; Gu Y
    Antiviral Res; 2024 Jun; 226():105898. PubMed ID: 38692413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.
    Valdovino-Navarro BJ; Dueñas S; Flores-Acosta GI; Gasperin-Bulbarela J; Bernaldez-Sarabia J; Cabanillas-Bernal O; Cervantes-Luevano KE; Licea-Navarro AF
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2.
    Wang S; Guo F; Liu K; Wang H; Rao S; Yang P; Jiang C
    Virus Res; 2008 Sep; 136(1-2):8-15. PubMed ID: 18554741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2.
    Cabanillas-Bernal O; Valdovinos-Navarro BJ; Cervantes-Luevano KE; Sanchez-Campos N; Licea-Navarro AF
    Front Immunol; 2023; 14():1257042. PubMed ID: 37753081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.
    Miller CJ; McGinnis JE; Martinez MJ; Wang G; Zhou J; Simmons E; Amet T; Abdeen SJ; Van Huysse JW; Bowsher RR; Kay BK
    N Biotechnol; 2021 May; 62():79-85. PubMed ID: 33556628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
    Lan J; Ge J; Yu J; Shan S; Zhou H; Fan S; Zhang Q; Shi X; Wang Q; Zhang L; Wang X
    Nature; 2020 May; 581(7807):215-220. PubMed ID: 32225176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection, identification and crystal structure of shark-derived single-domain antibodies against a green fluorescent protein.
    Chen YL; Xie XX; Zheng P; Zhu C; Ma H; Khalid Z; Xie YJ; Dang YZ; Ye Y; Sheng N; Zhong N; Lei WH; Zhang C; Zhang LJ; Jin T; Cao MJ
    Int J Biol Macromol; 2023 Aug; 247():125852. PubMed ID: 37460076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring SARS-CoV-2 Delta variant spike protein receptor-binding domain (RBD) as a target for tanshinones and antimalarials.
    Coghi P; Yun XY; Ng JPL; Law BYK; Memo M; Gianoncelli A; Wong VKW; Ribaudo G
    Nat Prod Res; 2022 Dec; 36(23):6150-6155. PubMed ID: 35337238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity.
    Chen WH; Hajduczki A; Martinez EJ; Bai H; Matz H; Hill TM; Lewitus E; Chang WC; Dawit L; Peterson CE; Rees PA; Ajayi AB; Golub ES; Swafford I; Dussupt V; David S; Mayer SV; Soman S; Kuklis C; Corbitt C; King J; Choe M; Sankhala RS; Thomas PV; Zemil M; Wieczorek L; Hart T; Duso D; Kummer L; Yan L; Sterling SL; Laing ED; Broder CC; Williams JK; Davidson E; Doranz BJ; Krebs SJ; Polonis VR; Paquin-Proulx D; Rolland M; Reiley WW; Gromowski GD; Modjarrad K; Dooley H; Joyce MG
    Nat Commun; 2023 Feb; 14(1):580. PubMed ID: 36737435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif.
    Fang Y; Sun P; Xie X; Du M; Du F; Ye J; Kalveram BK; Plante JA; Plante KS; Li B; Bai XC; Shi PY; Chen ZJ
    Sci Immunol; 2022 Oct; 7(76):eabp9962. PubMed ID: 35926067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.
    Ma H; Zeng W; Meng X; Huang X; Yang Y; Zhao D; Zhou P; Wang X; Zhao C; Sun Y; Wang P; Ou H; Hu X; Xiang Y; Jin T
    J Virol; 2021 Apr; 95(10):. PubMed ID: 33658349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.